Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
Biohaven Ltd. (BHVN)
RBC Capital analyst Leonid Timashev maintained a Buy rating on Biohaven Ltd. on May 28 and set a price target of $22.00. The company’s shares closed last Friday at $11.01.
According to TipRanks.com, Timashev is a 5-star analyst with an average return of 19.8% and a 55.7% success rate. Timashev covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Perspective Therapeutics, and Edgewise Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biohaven Ltd. with a $18.64 average price target, implying a 74.2% upside from current levels. In a report issued on May 28, Morgan Stanley also maintained a Buy rating on the stock with a $18.00 price target.
